Upstream Bio (UPB) Total Current Liabilities (2023 - 2026)
Upstream Bio (UPB) posted quarterly Total Current Liabilities of $13.7 million for Q1 2026, up 42.88% year-over-year from $9.6 million in Q1 2025, and up 1.61% quarter-over-quarter from $13.5 million in Q4 2025.
Upstream Bio (UPB) Total Current Liabilities (2023 - 2026) Analysis & Trends
Upstream Bio's Total Current Liabilities history runs 4 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 42.88% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (up 42.88% YoY), while the FY2025 annual figure was $13.5 million, up 25.29% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $13.7 million, up from $13.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $13.7 million in Q1 2026, with the low at $6.5 million in Q4 2023.
- The 4-year median for Total Current Liabilities is $10.9 million (2024), against an average of $11.0 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 64.8% in 2024, then rose 9.51% in 2025.
- Upstream Bio's Total Current Liabilities stood at $6.5 million in 2023, then surged by 64.8% to $10.7 million in 2024, then climbed by 25.29% to $13.5 million in 2025, then gained by 1.61% to $13.7 million in 2026.
- Business Quant data shows UPB's Total Current Liabilities at $13.7 million in Q1 2026, $13.5 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Upstream Bio | 387.23 Mn | 387.23 Mn | -3.29 Mn | 9.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.99 Mn |
| Mar 31, 2026 | 13.67 Mn |
| Dec 31, 2025 | 13.45 Mn |
| Sep 30, 2025 | 11.91 Mn |
| Jun 30, 2025 | 10.93 Mn |
| Mar 31, 2025 | 9.57 Mn |
| Dec 31, 2024 | 10.74 Mn |
| Sep 30, 2024 | 10.87 Mn |
| Dec 31, 2023 | 6.52 Mn |